Previous 10 | Next 10 |
2023-08-30 13:16:02 ET Gainers: NanoVibronix ( NAOV ) +127% . iCoreConnect ( ICCT ) +49% . Aravive ( ARAV ) +35% . AEON Biopharma ( AEON ) +33% . Alarum Technologies ( ALAR ) +25% . Greenland Technologies Holding Corporation ...
2023-08-30 08:24:12 ET Outlook Therapeutics ( OTLK ) -78% . FibroGen ( FGEN ) -23% announces topline results from LELANTOS-2, a phase 3 clinical study of Pamrevlumab. Ambarella ( AMBA ) -20% after Q2 earning release . MasterCraft Boat Holdings (...
2023-08-30 05:54:03 ET Related stories HP Inc. ( HPQ ) Q3 2023 Earnings Call Transcript Box, Inc. ( BOX ) Q2 2024 Earnings Call Transcript Ambarella, Inc. ( AMBA ) Q2 2024 Earnings Call Transcript Compare metrics for AMBA to BOX, HPQ Econo...
2023-08-29 16:50:43 ET More on FibroGen FibroGen, Inc. ( NASDAQ: FGEN ) Q2 2023 Earnings Call Transcript FibroGen, Inc. 2023 Q2 - Results - Earnings Call Presentation FibroGen's Unsteady Course: Assessing Fallout From IPF Failure And The Road Ahead Fi...
– Study did not meet the primary endpoint – – Pamrevlumab was generally safe and well tolerated – SAN FRANCISCO, Aug. 29, 2023 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced topline data from the Phase 3 LELANTOS-2 trial of pamre...
2023-08-08 16:29:52 ET BofA Securities has downgraded FibroGen ( NASDAQ: FGEN ) to underperform, citing an "unfavorable catalyst pathway" and the expected loss of Chinese market exclusivity of its anemia drug roxadustat around 2026. The investment bank said it views upcoming dat...
2023-08-07 22:10:25 ET FibroGen, Inc. (FGEN) Q2 2023 Earnings Conference Call August 7, 2023 5:00 PM ET Company Participants David DeLucia - Head of Corporate FP&A / Investor Relations Enrique Conterno - Chief Executive Officer Thane Wettig - Interim Chief Ex...
2023-08-07 16:28:43 ET FibroGen press release ( NASDAQ: FGEN ): Q2 GAAP EPS of -$0.90 misses by $0.16 . Revenue of $44.32M (+48.7% Y/Y) beats by $9.53M . We expect our cash, cash equivalents, investments, and accounts receivable to be sufficient to fund our ope...
Topline data from three late-stage pamrevlumab trials expected through 1H 2024, including the Pancreatic Cancer Action Network (PanCAN) Precision Promise SM Phase 2/3 study in metastatic pancreatic cancer Robust roxadustat volume growth of over 40% in China ...
2023-07-25 08:20:12 ET FibroGen ( NASDAQ: FGEN ) appoints Thane Wettig as the company’s interim CEO effective as of July 23, 2023. Mr. Wettig has served as FibroGen’s chief commercial officer and a key member of the senior leadership team since June...
News, Short Squeeze, Breakout and More Instantly...
SAN FRANCISCO, June 18, 2024 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced it will host the second part of its virtual KOL investor event series on Wednesday, June 26, 2024 at 10:00 AM ET. To register, click here . The event will feature Rahul Aggarwal, M.D. (Uni...
2024-06-12 09:44:18 ET USA News Group Commentary Issued on behalf of Oncolytics Biotech Inc. VANCOUVER – June 12, 2024 – USA News Group – After looking at public health records for 3.8 million patients with invasive spreading cancer, researchers recently discovere...
FibroGen to evaluate FG-3165, an anti-galectin 9 (Gal9) monoclonal antibody (mAb), as monotherapy treatment as well as in combination with LIBTAYO ® in patients with select solid tumors FibroGen to evaluate FG-3175, an anti-c-c motif chemokine receptor 8 (CCR8) mAb, a...